Gilead Sciences Files 8-K on Financials

TL;DR

Gilead dropped an 8-K on Nov 6th with financial results. Check it out.

AI Summary

On November 6, 2024, Gilead Sciences, Inc. filed an 8-K report detailing results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 333 Lakeside Drive, Foster City, California.

Why It Matters

This 8-K filing provides investors with crucial updates on Gilead Sciences' financial performance and operational results, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any unusual or significant risks.

Key Players & Entities

• GILEAD SCIENCES, INC. (company) — Registrant
• November 6, 2024 (date) — Date of Report
• 333 Lakeside Drive, Foster City, California (location) — Principal executive offices
• Delaware (location) — State of Incorporation

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select

Filing Documents

• gild-20241106.htm (8-K) — 32KB
• exhibit991earningspressrel.htm (EX-99.1) — 694KB
• gilead_transparentxlogoxsta.jpg (GRAPHIC) — 36KB
• 0000882095-24-000025.txt ( ) — 936KB
• gild-20241106.xsd (EX-101.SCH) — 2KB
• gild-20241106_lab.xml (EX-101.LAB) — 21KB
• gild-20241106_pre.xml (EX-101.PRE) — 12KB
• gild-20241106_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On November 6, 2024 , Gilead Sciences, Inc., a Delaware corporation ("Gilead"), issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is filed as Exhibit 99.1 to this report. Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles ("GAAP") and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 10, 11 and 12 of the press release filed as Exhibit 99.1 to this report. The information in Item 2.02 and Item 9.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. Section 9 - FINANCIAL STATEMENTS AND EXHIBITS

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, issued by Gilead Sciences, Inc. on November 6, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GILEAD SCIENCES, INC. (Registrant) /s/ ANDREW D. DICKINSON Andrew D. Dickinson Chief Financial Officer Date: November 6, 2024 Exhibit Index Exhibit Number Description 99.1 Press Release, issued by Gilead Sciences, Inc. on November 6, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

View Full Filing

View this 8-K filing on SEC EDGAR